RVX Resverlogix Corp.

0.0524USD0.0750 CAD · TSX0.00%Mkt Cap: 18.05M USDP/E: —

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal…

Institutional holders1 on file

Key Statistics

Company
Market Cap18.05M USD
Enterprise Value81.92M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.77M USD
Revenue/Share—
Last Price0.0524 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA76128M1086
Valuation
P/E (Trailing)—
P/E (Forward)-0.34
PEG—
EV/EBITDA-24.56
EV/Revenue—
P/S—
P/B-0.17
EPS (TTM)-0.04 USD
EPS (Forward)-0.22 USD
52W Range
0.04896% of range0.1049
52W High0.1049 USD
52W Low0.0489 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE8.73%
ROA-97.72%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.66M USD
CapEx (TTM)696.00K USD
FCF Margin—
FCF Yield-23.50%
Net Debt91.37M USD
Net Debt/EBITDA-19.15
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.23
Current Ratio0.04
Quick Ratio0.03
Book Value/Sh-0.43 USD
Cash/Share0.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.344.29M
Float251.22M
Insiders26.36%
Institutions0.00%
Short Interest
Short Ratio0.5d
Short % Out.0.00%
Shares Short12.06K
Short (prev mo.)60
Technical
SMA 500.0605 (-13.4%)
SMA 2000.0699 (-25.0%)
Beta0.96
S&P 52W Chg12.00%
Avg Vol (30d)39.33K
Avg Vol (10d)52.21K
Technical Indicators
RSI (14)42.5
MACD-0.0031
MACD Signal-0.0035
MACD Hist.+0.0003
BB Upper0.0588 USD
BB Middle0.0540 USD
BB Lower0.0492 USD
BB Width17.77%
ATR (14)0.0026 USD
Vol Ratio (20d)0.28x

About Resverlogix (TSE: RVX)

›

Resverlogix (TSE: RVX) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.0750 CAD on 19 November 2026, down 31.8% over 52 weeks. Its 52-week range is 0.0700 CAD to 0.1500 CAD: the price is 50.0% below the high and 7.1% above the low.

Its market capitalisation is 25.82M CAD.

Resverlogix reports return on equity of 8.7% and an operating margin of 0.0%.

Its debt exceeds its cash by 91.37M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.